BSE Code: | NSE Code: | ISIN: | Sector:
Research Report Detail
|Report Date||Call||Price@Call||Target Price
|Current Status||Time Horizon|
|Closed|| Medium (6M)
Nirmal Bang Recommends 'Buy' On Aurobindo Pharma
According to Nirmal Bang, Aurobindo Pharma should post flat earnings on a quarter-on-quarter basis as there are no major approvals in the US incrementally which can materially change the performance. The company's Europe business will reflect similar trends, the brokerage adds.